SCHEMBL3574274

SCHEMBL3574274

NC(=O)c1cccc(Cc2ccc3c(c2)C(=CNc2ccc(N4CCOCC4)cc2)C(=O)N3)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.46
AKT2 P31751 2/20 0.42
PDGFRB P09619 2/20 0.41
SIRT2 Q8IXJ6 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
SIRT3 Q9NTG7 1/20 0.41
CSF1R P07333 1/20 0.41
ERBB2 P04626 1/20 0.39
RET P07949 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
PAK1 Q13153 3/20 0.39
CHEK1 O14757 2/20 0.38
CHEK2 O96017 1/20 0.38
KIT P10721 1/20 0.38
MARK3 P27448 1/20 0.38
MAPK1 P28482 1/20 0.38
AKT1 P31749 1/20 0.38
MARK2 Q7KZI7 1/20 0.38
AURKB Q96GD4 1/20 0.38
RORC P51449 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3570303 0.92 AKT2 (0.43) PARP1AKT2PDGFRBSIRT2SIRT1
SCHEMBL3576546 0.91 PTK2 (0.43) PARP1AKT2CSF1RRETMAPK1
SCHEMBL3574278 0.88 PDGFRB (0.44) PARP1AKT2PDGFRBCSF1RERBB2
SCHEMBL3569087 0.87 PDGFRB (0.43) AKT2PDGFRBSIRT2SIRT1SIRT3
SCHEMBL4755940 0.87 PDGFRB (0.43) AKT2PDGFRBSIRT2SIRT1SIRT3
SCHEMBL4703846 0.86 LCK (0.45) PARP1AKT2PDGFRBCSF1RRET
SCHEMBL5449435 0.86 LCK (0.45) PARP1AKT2PDGFRBCSF1RRET
SCHEMBL3570305 0.85 PDGFRB (0.44) AKT2PDGFRBCSF1RERBB2RET
SCHEMBL3576911 0.84 CSF1R (0.47) PARP1CSF1RMAPK1
SCHEMBL4705955 0.84 CSF1R (0.46) PDGFRBCSF1RRETPAK1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US claimed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 PARP1 2019/4885AKT2 168/4885PDGFRB 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.